抗 TIGIT 抗體市場：市場機會和臨床試驗趨勢 (2024)

TIGIT 是一種免疫檢查點抑製劑，最近成為通過調節其在體內活性發揮作用的藥物的靶標。 TIGIT 已開發出拮抗劑和激動劑，其中前者占主導地位，主要用於各種類型的人類疾病。 TIGIT 抑製劑似乎遵循與免疫檢查點抑製劑類似的趨勢，這些抑製劑已針對各種癌症進行了廣泛的測試，這表明這些新型抑製劑證明了類似抑製劑所證明的治療成功性。目前正在進行多項臨床前和臨床試驗，以評估這是否可以復制。 其中幾種 TIGIT 抑製劑現已接近監管部門的批准，並被認為是開發針對 TIGIT 的藥物的主要推動力。

近幾十年來，免疫檢查點蛋白因其作為治療靶點的潛力而引起了人們的極大興趣。 TIGIT 等檢查點蛋白在調節免疫系統中發揮著重要作用，它們的激活和抑制可能對身體產生有益或致命的後果，具體取決於疾病的適應症，也可能導致負面結果。 近年來，研究人員發現了新的免疫檢查點蛋白，其中包括十多年前發現的 TIGIT。 該蛋白具有三個配體：TIGIT具有三個配體，CD155、CD112和CD113，它們都是Nectin和NECL分子家族的成員。

TIGIT 已被證明可以下調消除癌細胞所需的 T 細胞和 NK 細胞的活性，在癌症免疫週期的許多方面充當屏障。 臨床前研究表明，TIGIT 阻斷可以預防多種實體癌和血液癌。 在病毒和細菌感染中也進行了類似的觀察，其中免疫系統的激活（對於免疫介導的感染細胞清除至關重要）被 TIGIT 激活所阻止。

為了抑制人TIGIT的抑制活性，已經生產了AZD2936、PM1009、Domvanalimab和PM1021等單克隆抗體和雙特異性抗體。 TIGIT 抑制正在作為單一藥物或與抗 PD-1/PD-L1 單克隆抗體聯合治療晚期實體瘤患者進行臨床研究。

另一方面，在自身免疫性疾病的研究中，TIGIT 與疾病活動相關。 一組科學家宣布開發出抗小鼠 TIGIT 激動劑單克隆抗體。 這種激動性TIGIT抗體用於實驗性自身免疫性腦脊髓炎模型小鼠，據稱通過作用於兩種不同效果的細胞並抑制T細胞活化來改善疾病症狀。我做到了。 因此，TIGIT診斷抗體具有減少自身免疫性疾病中T細胞失衡的能力，有望在自身免疫性疾病的治療中特別有效。

目前，臨床試驗中用於治療自身免疫性疾病的TIGIT抗體均無拮抗作用。 同樣，臨床試驗中也沒有用於治療病毒或細菌感染的拮抗抗體。

全球領先的製藥公司正在開發 TIGIT 靶向藥物，包括百時美施貴寶、羅氏、阿斯利康、Bioteus、Arcus Biosciences、百濟神州、康方生物和 Compugen。 這些公司與耶魯大學、匹茲堡大學和 MD 安德森癌症中心等大學和醫療機構合作，推動候選藥物通過臨床試驗。 其中一些候選藥物目前正處於臨床試驗的最後階段，預計將獲得監管部門的批准。

目前，針對TIGIT的藥物未來市場前景看好。 此外，TIGIT 激動劑和拮抗劑的治療在癌症以外的適應症中顯示出前景，並且廣泛的抗 TIGIT 藥物表明了疾病擴展的潛力。 首個TIGIT蛋白靶向藥物預計將在未來幾年內上市，引發一系列藥物研發和商業化項目，加大投資力度，開發優化的抗TIGIT藥物。使能夠 此外，隨著人工智能和納米技術進入藥物發現、開發和藥物輸送過程，擁有人工智能和納米技術基礎的公司預計將在 TIGIT 治療行業中獲得越來越突出和重要的地位。

本報告調查了全球抗TIGIT 抗體市場，並提供了市場概述、臨床試驗趨勢、按適應症劃分的臨床管道趨勢、患者細分和不同的臨床管道趨勢，以及進入該領域的公司的競爭格局市場.等等。

內容

第一章抗TIGIT抗體簡介

第 2 章抗 TIGIT 抗體的作用（按適應症）

• 癌症
• 病毒感染
• 自身免疫性疾病

第 3 章 PD1 或 PDL1 抑制 TIGIT

第4章全球抗TIGIT抗體臨床試驗概述

• 按公司
• 按國家/地區
• 按指示
• 按患者細分
• 愛別

第 5 章按公司、適應症和階段劃分的全球抗 TIGIT 抗體臨床管道

• 調查
• 臨床前
• 第一階段
• 第一/二期
• 第二階段
• 第三階段

第6章全球抗TIGIT抗體市場動態

第7章全球抗TIGIT抗體市場未來展望

第8章競爭態勢

• Akeso Biopharma
• BeiGene
• Bio-Thera Solutions
• Biotheus
• Compugen
• FutureGen Biopharmaceutical
• Merck Sharp & Dohme
• Nanjing Sanhome Pharmaceutical
• OriCell Therapeutics
• Phio Pharmaceuticals
• Roche
• Shanghai Henlius Biotech
• Shanghai Junshi Biosciences
• Simcere Pharmaceutical Group
• Tasrif Pharmaceutical

“Anti TIGIT Antibody Market Opportunity & Clinical Trials Insight 2024 ” Report Highlights:

• Clinical Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
• Anti TIGIT Antibodies In Clinical Trials : > 40
• Role of TIGIT Inhibitors by Indication
• Global Anti TIGIT Antibodies Market Dynamics
• Anti TIGIT Antibodies Market Future Outlook
• Key Companies Profile Involved in Development Of Anti TIGIT Antibodies

TIGIT is one of the most recent immune checkpoint inhibitors to emerge as a target for drugs that work by modulating its activity in the body. Both antagonists and agonists have been developed against the TIGIT, with the former predominating, and are mostly used in human diseases spanning various types. TIGIT inhibitors appear to be following a similar trend to immune checkpoint inhibitors, which have been widely tested against various cancers, and several preclinical and clinical studies are now being conducted to assess whether these novel inhibitors can replicate the therapeutic success shown by their counterparts. Several of these TIGIT inhibitors are now close to receiving regulatory approval, which is regarded to be a major driver for the development of TIGIT-targeting drugs.

Immune checkpoint proteins have gotten a lot of interest in the last few decades or so because of their potential as therapeutic targets. Checkpoint proteins such as TIGIT play a vital role in immune system control, and their activation and repression can have both beneficial and fatal consequences on the body depending on the disease indication. In recent years, researchers have found new immunological checkpoint proteins, including TIGIT, which was discovered a little more than a decade ago. The protein has three ligands: CD155, CD112, and CD113, which are all members of the nectin and NECL molecular families.

TIGIT has been found to downregulate the activity of T cells and NK cells, both of which are required for cancer cell elimination, acting as a hindrance to many aspects of the cancer immunity cycle. TIGIT blocking has been shown in preclinical tests to protect against a variety of solid and hematological malignancies. The similar thing has been observed in viral and bacterial infections, when immune system activation is essential for immune-mediated clearance of infected cells, which is hampered by TIGIT activation.

Several monoclonal and bispecific antibodies like AZD2936, PM1009, Domvanalimab and PM1021 have been produced to suppress the inhibitory activity of human TIGIT. TIGIT blocking is being studied in clinical studies as a monotherapy or in conjunction with anti-PD-1/PD-L1 monoclonal antibodies for the treatment of patients with advanced solid tumors.

TIGIT, on the other hand, has been linked to disease activity according to research on autoimmune diseases. A team of scientists announced the development of anti-mouse-TIGIT agonistic monoclonal antibody. The agonistic TIGIT antibody was utilized in mice models of experimental autoimmune encephalomyelitis, where it was claimed to improve disease symptoms by blocking T cell activation by acting on two different types of cells with differing effects. As a result, TIGIT-agnostic antibodies have the ability to reduce T cell imbalance in autoimmune disorders and are predicted to be especially effective in the treatment of autoimmune diseases.

There are currently no TIGIT antibodies with agonistic characteristics in clinical trials for the treatment of autoimmune disorders. Similarly, no antagonistic antibodies have entered clinical trials for the treatment of viral and bacterial infections, making both of these fields worthwhile to investigate given their enormous future potential.

A number of major global pharmaceutical companies, including Bristol-Myers Squibb, Roche, AstraZeneca, Biotheus, Arcus Biosciences, BeiGene, Akeso, and Compugen, are developing TIGIT-targeting drugs. To get their candidates through clinical trials, these companies have partnered with universities and health institutions such as Yale University, the University of Pittsburgh, and the MD Anderson Cancer Center. Some of these candidates are now in the final stages of clinical studies and show promise for regulatory approval.

Currently, the future market for TIGIT-targeting pharmaceuticals appears to be promising. Furthermore, with indications other than cancer showing promise for treatment with TIGIT agonists and antagonists, the breadth of anti-TIGIT drugs shows promise for disease expansion. The first TIGIT protein-targeting drug is expected to hit the market within the next 2-3 years, which will spark a rush of drug research, development, and commercialization deals, increased investment, and the development of technology platforms to allow the development of optimized anti-TIGIT drugs. Furthermore, as AI and nanotechnology join the drug discovery, development, and delivery processes, companies with AI and nanotechnology foundations are projected to become increasingly visible and significant in the TIGIT drugs industry.

Table of Contents

1. Introduction to Anti TIGIT Antibody

• 1.1. Overview
• 1.2. Mechanism of Anti TIGIT Antibodies
• 1.3. Clinical Approaches to Target TIGIT

2. Role of Anti TIGIT Antibody by Indication

• 2.1. Cancer
• 2.2. Viral Infections
• 2.3. Autoimmune Disorders

3. TIGIT Co Inhibition with PD1 or PDL1

4. Global Anti TIGIT Antibodies Clinical Trials Overview

• 4.1. By Company
• 4.2. By Country
• 4.3. By Indication
• 4.4. By Patient Segment
• 4.5. By Phase

5. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication & Phase

• 5.1. Research
• 5.2. Preclinical
• 5.3. Phase-I
• 5.4. Phase-I/II
• 5.5. Phase-II
• 5.6. Phase-III

6. Global Anti TIGIT Antibodies Market Dynamics

• 6.1. Market Drivers
• 6.2. Commercialization Challenges

7. Global Anti TIGIT Antibodies Market Future Outlook

8. Competitive Landscape

• 8.1. Akeso Biopharma
• 8.2. BeiGene
• 8.3. Bio-Thera Solutions
• 8.4. Biotheus
• 8.5. Compugen
• 8.6. FutureGen Biopharmaceutical
• 8.7. Merck Sharp & Dohme
• 8.8. Nanjing Sanhome Pharmaceutical
• 8.9. OriCell Therapeutics
• 8.10. Phio Pharmaceuticals
• 8.11. Roche
• 8.12. Shanghai Henlius Biotech
• 8.13. Shanghai Junshi Biosciences
• 8.14. Simcere Pharmaceutical Group
• 8.15. Tasrif Pharmaceutical

List of Figures

• Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
• Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action
• Figure 1-3: TIGIT Inhibitor - Mechanism of Action
• Figure 1-4: Binding Efficacy of Monoclonal Antibody
• Figure 1-5: Binding Efficacy of Bispecific Antibodies
• Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
• Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
• Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
• Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
• Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
• Figure 2-5: TIGIT Associated Autoimmune Disorders
• Figure 4-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2023 - 2024
• Figure 4-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2023 - 2024
• Figure 4-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2023 - 2024
• Figure 4-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2023 - 2024
• Figure 4-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2023 - 2024
• Figure 6-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
• Figure 6-2: TIGIT Inhibitor Market Drivers
• Figure 6-3: Stages of Drug Development